Mark W Jensen

US Patent:

7890511, Feb 15, 2011

Filed:

Feb 5, 2008

Appl. No.:

12/026475

Inventors:

Mikko Valimaki - Orem UT, US
Joshua Dinerstein - West Valley UT, US
Mark Jensen - Bluffdale UT, US
J. Michael Fonnesbeck - Lehi UT, US
James Pettit Whitechurch - Draper UT, US
John Lyman Ahlander - Orem UT, US

Assignee:

Blue Coat Systems, Inc. - Sunnyvale CA

International Classification:

G06F 17/30

US Classification:

707737

Abstract:

A log file from a server is analyzed and entries in the log file are deleted, combined, or condensed to create a list of page views that more accurately reflects traffic to a server. The list of page views may be added to a database for searching, sorting, and analyzing the page views.

US Patent:

20210352892, Nov 18, 2021

Filed:

Apr 10, 2020

Appl. No.:

17/044657

Inventors:

- Salt Lake City UT, US
Kyle Isaacson - Salt Lake City UT, US
Mark Jensen - Pleasant Grove UT, US
Nithya Subrahmanyam - Salt Lake City UT, US

International Classification:

A01N 25/10
A01N 37/40
C08L 67/03

Abstract:

The invention generally relates to agrochemical compositions and methods of making and using same. Specifically, the disclosed agrochemical compositions comprise high molecular weight non-polymeric residues or polymer backbones, and pesticide residues covalently attached thereto. Such compositions can be useful in, for example, controlling plant growth. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

US Patent:

20210060037, Mar 4, 2021

Filed:

Nov 17, 2020

Appl. No.:

16/950387

Inventors:

- Salt Lake City UT, US
Joseph Cappello - Salt Lake City UT, US
Azadeh Poursaid - Salt Lake City UT, US
Mark Martin Jensen - Salt Lake City UT, US

International Classification:

A61K 31/65
A61K 9/06
A61K 47/42
A61K 31/44
A61K 9/14
A61K 9/00

Abstract:

Described herein are chemoembolic compositions and agents. The compositions include one or more anti-cancer agents and a silk-elastinlike protein polymer, wherein the compositions are liquids prior to administration to a subject but convert to hydrogels upon administration to the subject. Administration of the Chemoembolic compositions to tumor and/or tumor vasculature in a subject having cancer can result in reduced or inhibited blood flow to the tumor as well as localized, sustained release of the anti-cancer agent in the vicinity of the tumor. Reduction in blood flow, in turn, results in a reduction of tumor volume and/or inhibition of tumor growth, while localized release of the anti-cancer agent results in reduced systemic effects and lower overall toxicity of treatment with the compositions.

US Patent:

20190209606, Jul 11, 2019

Filed:

Sep 14, 2017

Appl. No.:

16/333434

Inventors:

- Salt Lake City UT, US
Siam OOTTAMASATHIEN - Salt Lake City UT, US
Mark Martin JENSEN - Salt Lake City UT, US
Joseph CAPPELLO - Salt Lake City UT, US
Wanjian JIA - Salt Lake City UT, US
Glenn D. PRESTWICH - Salt Lake City UT, US

Assignee:

UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT

International Classification:

A61K 31/737
A61K 9/00
A61K 9/06
A61K 31/728
A61K 47/42
A61K 45/06
A61P 29/00

Abstract:

Described herein are in situ gelling compositions. The compositions include an anti-inflammatory polysaccharide and a gelling polymer, wherein the composition is a liquid prior to administration to a subject but converts to a gel upon administration to the subject. The compositions described herein have numerous applications with respect to the local treatment (reduction or prevention) of inflammation and/or tissue damage.

US Patent:

20180353522, Dec 13, 2018

Filed:

Jun 12, 2018

Appl. No.:

16/006015

Inventors:

- Salt Lake City UT, US
Joseph Cappello - Salt Lake City UT, US
Azadeh Poursaid - Salt Lake City UT, US
Mark Martin Jensen - Salt Lake City UT, US

Assignee:

UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT

International Classification:

A61K 31/65
A61K 31/44
A61K 47/42
A61K 9/06

Abstract:

Described herein are chemoembolic compositions and agents. The compositions include one or more anti-cancer agents and a silk-elastinlike protein polymer, wherein the compositions are liquids prior to administration to a subject but convert to hydrogels upon administration to the subject. Administration of the chemoembolic compositions to tumor and/or tumor vasculature in a subject having cancer can result in reduced or inhibited blood flow to the tumor as well as localized, sustained release of the anti-cancer agent in the vicinity of the tumor. Reduction in blood flow, in turn, results in a reduction of tumor volume and/or inhibition of tumor growth, while localized release of the anti-cancer agent results in reduced systemic effects and lower overall toxicity of treatment with the compositions.